PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 3912: NQO1 as a target to overcome therapy resistance in multiple myeloma.

View Full Paper
Ask AI
Bookmark
Share

Authors

SHSeungbin HanCVChristina VerbruggenLBLenka Bešše

Discussion

Loading...

Member takes

Overview

Investigates NQO1's role in treatment resistance in multiple myeloma, indicating it as a target for improved therapies.

Key Points

  • This research aims to clarify the role of NQO1 in therapy resistance in multiple myeloma, focusing on its expression and impact on treatment outcomes.
  • RNA-seq performed on bone marrow-derived CD138+ cells from newly diagnosed and relapsed/refractory multiple myeloma patients.
  • Quantification of immunotherapy targets using direct stochastic Optical Reconstruction Microscopy (dSTORM).
  • Sensitivity to proteasome inhibitors and immunomodulatory drugs assessed using AlamarBlue assays.
  • NQO1^high multiple myeloma cells treated with NQO1 inhibitor ES936 to evaluate changes in sensitivity.
  • NQO1 expression significantly higher in relapsed/refractory myeloma compared to newly diagnosed patients.
  • NQO1 overexpression increased IC50 for bortezomib and carfilzomib; sensitivity to IMiDs maintained.
  • Inhibiting NQO1 restored proteasome inhibitor sensitivity and CD38 expression in myeloma cell lines.
  • No changes in CD38 mRNA levels, suggesting a post-translational mechanism related to protein stability or trafficking.

Cite This Study

Han et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd29a79560c99a0a30b2https://doi.org/10.1158/1538-7445.am2026-3912
View Full Paper
Ask AI
Bookmark
Share